Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SNSE

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNSE
DateTimeSourceHeadlineSymbolCompany
14/06/202407:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
14/06/202407:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
14/06/202407:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
14/06/202407:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
14/06/202407:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
14/06/202406:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
03/06/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
24/05/202407:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
10/05/202406:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
09/05/202421:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
06/03/202408:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
28/02/202423:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
17/02/202410:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
17/02/202410:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
17/02/202410:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
09/02/202408:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
05/01/202400:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
08/11/202308:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
07/11/202323:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
07/11/202323:30GlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
06/11/202322:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
04/11/202307:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
04/11/202307:05GlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
03/11/202307:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
03/11/202307:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
01/11/202322:30GlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
26/10/202300:05GlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
23/10/202322:30GlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
21/10/202308:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
27/09/202321:30GlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SNSE